The Effects of Hydromorphone on Responses to Verbal Tasks (HESS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02205983 |
|
Recruitment Status :
Completed
First Posted : August 1, 2014
Results First Posted : October 9, 2018
Last Update Posted : October 9, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Healthy | Drug: 2 mg hydromorphone Drug: 1000 mg Acetaminophen Drug: 4 mg hydromorphone Drug: dextrose | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 50 participants |
| Allocation: | Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
| Primary Purpose: | Basic Science |
| Official Title: | The Effects of Hydromorphone on Responses to Verbal Tasks |
| Actual Study Start Date : | January 2015 |
| Actual Primary Completion Date : | July 2016 |
| Actual Study Completion Date : | September 2016 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: 2 mg hydromophone
Healthy adult volunteers will receive 2 mg hydromophone. Hydromorphone is a mu-opioid agonist used clinically for pain management. Plasma concentrations of hydromorphone peak approximately 60 min after ingestion.
|
Drug: 2 mg hydromorphone
We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task. |
|
Experimental: 4 mg hydromphone
Healthy adult volunteers will receive 4 mg hydromophone. Hydromorphone is a mu-opioid agonist used clinically for pain management. Plasma concentrations of hydromorphone peak approximately 60 min after ingestion
|
Drug: 4 mg hydromorphone
We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task. |
|
Experimental: 1000 mg acetaminophen
Healthy adult volunteers will receive 1000 mg acetaminophen. Acetaminophen is a COX inhibitor that is used clinically as an analgesic and antipyretic. The dose administered here has been shown to reduce neural and subjective responses to social rejection, and it also peaks about 60 min after ingestion.
|
Drug: 1000 mg Acetaminophen
We are administering sublingual buprenorphine to healthy volunteers to measure its effects on the performance of a verbal task. |
|
Placebo Comparator: Dextrose
Healthy adult volunteers will recieve Dextrose (placebo).
|
Drug: dextrose
We are administering dextrose to healthy volunteers for our placebo group. |
- Subjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Subscales of the Drug Effects Questionnaire [ Time Frame: End of study (time 0 and approximately 4 weeks later), week 4 reported. ]The Drug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: "Feel Drug", "Feel High", "Like Drug", and "Want More". The "Feel Drug", "Feel High", "Like Drug", and "Want More" subscales are reported. All subscales are scored on a visual analogue scale (scroll bar on computer screen) ranging from 0-100. 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome. The values shown below are only from week 4
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 40 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy adult volunteers
Exclusion Criteria:
- any current medical condition requiring medication or abnormal electrocardiogram
- current or past medical condition considered to be a contraindication for the study conditions
- any current Axis I psychiatric disorder (APA, 1994) including Substance Use Disorder, or Anxiety Disorder or Major Depression in the past year, any history of psychosis
- less than high school education
- lack of fluency in English
- night shift work
- Pregnancy, lactation or plans to become pregnant.
- Use of hormonal contraception.
- Daily cigarette smokers i.e., >7 cigarettes per week
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02205983
| United States, Illinois | |
| University of Chicago Hospital | |
| Chicago, Illinois, United States, 60637 | |
| Principal Investigator: | Harriet de Wit, PhD | University of Chicago | |
| Study Chair: | Jerome Jaffe, MD | University of Maryland |
| Responsible Party: | University of Chicago |
| ClinicalTrials.gov Identifier: | NCT02205983 |
| Other Study ID Numbers: |
UC13-1027 R01DA002812 ( U.S. NIH Grant/Contract ) |
| First Posted: | August 1, 2014 Key Record Dates |
| Results First Posted: | October 9, 2018 |
| Last Update Posted: | October 9, 2018 |
| Last Verified: | September 2018 |
|
enrolling adult volunteers |
|
Acetaminophen Hydromorphone Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents |
Physiological Effects of Drugs Antipyretics Analgesics, Opioid Narcotics Central Nervous System Depressants |

